Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

CEL-SCI Corporation announced that its longstanding collaboration with Northeast Ohio Medical University has produced a new investigational breast cancer vaccine which prevents and treats a HER-2/neu expressing breast cancer tumor in a mouse model of the disease.

31 Jan 2013

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

ImmunoCellular Therapeutics, Ltd. announced that the US Food and Drug Administration (FDA) has allowed the investigational new drug (IND) application for ICT-140, paving the way for conducting a clinical trial.

30 Jan 2013

Antibodies essential for dendritic cell maturation

Dendritic cells, or DCs for short, perform a vital role for the immune system: They engulf pathogens, break them down into their component parts, and then display the pieces on their surface.

23 Jan 2013

Study explains how Timothy syndrome mutation causes wiring defects that underlie cognition

A new finding in neuroscience for the first time points to a developmental mechanism linking the disease-causing mutation in an autism-related disorder, Timothy syndrome, and observed defects in brain wiring, according to a study led by scientist Ricardo Dolmetsch and published online yesterday in Nature Neuroscience.

16 Jan 2013

Vaccine gives HIV patients a long-term boost

A functional cure for HIV-1 seems feasible after research shows that an immunotherapeutic vaccine demonstrated long-term efficacy at reducing viral load when administered to patients in the early stages of disease.

7 Jan 2013

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.

15 Nov 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

IL-36 might be a useful therapeutic target in treatment of psoriasis

Psoriasis is a chronic inflammatory skin disorder that affects approximately 2% of the world's population. A group of inflammatory molecules known as interleukins activate an immune response that causes itchy skin, but it is unclear how the skin cells and immune cells communicate.

16 Oct 2012

Autoimmune disease myasthenia gravis halted in mice

Working with mice, Johns Hopkins researchers say they have developed a gene-based therapy to stop the rodent equivalent of the autoimmune disease myasthenia gravis by specifically targeting the destructive immune response the disorder triggers in the body.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

Neuronal inhibition plays key role in memory formation

Stefan Remy and colleagues at the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn have illuminated how this system works. "The system acts like a filter, only letting the most important impulses pass," explains Remy. "This produces the targeted neuronal patterns that are indispensible for long-term memory storage."

7 Sep 2012

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

ImmunoCellular Therapeutics, Ltd. announced today that the company has completed enrollment for its Phase II randomized, double-blinded, placebo-controlled, multi-center trial of its dendritic cell-based cancer vaccine ICT-107 for treatment of glioblastoma.

6 Sep 2012

Gene therapy approach restores ability to smell in mouse model of congenital anosmia

Scientists funded by the National Institutes of Health have restored the ability to smell in a mouse model of a human genetic disorder that causes congenital anosmia-the inability to smell from birth. The approach uses gene therapy to regrow cilia, cell structures that are essential for olfactory function.

3 Sep 2012

Scientists restore sense of smell in mice through gene therapy

Scientists have restored the sense of smell in mice through gene therapy for the first time -- a hopeful sign for people who can't smell anything from birth or lose it due to disease.

3 Sep 2012

Study explains why some cancer vaccines are not as effective as hoped

A research report published in the September 2012 issue of the Journal of Leukocyte Biology offers a possible explanation of why some cancer vaccines are not as effective as hoped, while at the same time identifies a new therapeutic strategy for treating autoimmune problems. In the report, scientists suggest that cancer, even in the very early stages, produces a negative immune response from dendritic cells, which prevent lymphocytes from working against the disease.

31 Aug 2012

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

Northwest Biotherapeutics announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom, for the Company's 300-patient Phase III clinical trial of DCVax-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

24 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

ImmunoCellular Therapeutics announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy.

9 Aug 2012

Promising implications for improving cellular immunotherapy for treatment of cancer

New research from the Trudeau Institute laboratory of Dr. Edward L. Pearce (Washington University) has promising implications for improving a treatment for cancer known as cellular immunotherapy. The findings were just published in the The Journal of Immunology.

30 Jul 2012

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Northeast Ohio Medical University, CEL-SCI produce new investigational breast cancer vaccine

FDA allows IND application for ImmunoCellular’s ICT-140 to treat ovarian cancer

Antibodies essential for dendritic cell maturation

Study explains how Timothy syndrome mutation causes wiring defects that underlie cognition

Vaccine gives HIV patients a long-term boost

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

IL-36 might be a useful therapeutic target in treatment of psoriasis

Autoimmune disease myasthenia gravis halted in mice

Researchers identify how p110delta molecule controls the body's inflammatory responses

Neuronal inhibition plays key role in memory formation

ImmunoCellular completes enrollment in ICT-107 Phase II trial for glioblastoma

Gene therapy approach restores ability to smell in mouse model of congenital anosmia

Scientists restore sense of smell in mice through gene therapy

Study explains why some cancer vaccines are not as effective as hoped

NW Bio receives MHRA approval to initiate DCVax-L Phase III GBM brain cancer trial in the U.K.

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Data from IMUC’s ICT-107 Phase I trial on glioblastoma multiforme accepted for publication

Promising implications for improving cellular immunotherapy for treatment of cancer

Immunology eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Dendritic Cell News and Research

Latest Dendritic Cell News and Research

Immunology eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in